Please login to the form below
Mediator
This page shows the latest Mediator news and features for those working in and with pharma, biotech and healthcare.
Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib
Sanofi’s investigational BTK inhibitor, tolebrutinib, has been shown to have a significant effect on the key central nervous system immune mediators that may drive multiple sclerosis (MS) disease progression, according
Latest news
-
BioXcel Therapeutics doses first patient in phase 3 Alzheimer’s-associated agitation trial
BioXcel believes that BXCL501 potentially targets an important mediator of agitation, and the company has observed anti-agitation results in multiple clinical studies across several neuropsychiatric disorders.
-
Biogen doses first patient with litifilimab in cutaneous lupus erythematosus study
These pro-inflammatory mediators are thought to play a major role in the pathogenesis of systemic and cutaneous lupus, Biogen explained in a statement.
-
Positive results for Biogen’s lupus drug published in NEJM
Such inflammatory mediators are believed to be key in the pathogenesis of systemic and cutaneous lupus.
-
UK Supreme Court rules in favour of Servier in NHS patent lawsuit
drug Mediator (benfluorex) in March. ... First launched in 1976, Mediator was not taken off the market in France until 2009, several years after being withdrawn from other European countries, including Spain in 2003 and Italy in
-
Biogen doses first patient in phase 3 systemic lupus erythematosus study
This receptor has been previously shown to reduce inflammatory cytokine production from pDCs, including type-I IFN (IFN-I) – inflammatory mediators are believed to play a major role in the pathogenesis
More from news
Approximately 1 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
After the wildfire: how will healthcare recover from the pandemic?
mediator diminishing.
-
Cortellis Drugs to Watch in 2020 report
of the JAK family of kinases leads to an aberrant production of pro-inflammatory mediators, which are involved in the pathogenesis of rheumatoid arthritis, and inhibition of JAK proteins is an
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Dysfunction in the regulation of the JAK family of molecules is implicated in the aberrant production of pro-inflammatory mediators that are involved in the pathogenesis of rheumatoid arthritis, and inhibition
-
Case study: From Clinical Trials to Real-World Evidence
on Product X’s real-world experience and heritage within dermatology and rheumatology, since these diseases share a common inflammatory mediator targeted by Product X.
-
Searching for health
The task of conducting the diverse themes needed for innovation is never easy and, in France, it is made even harder by the lingering echoes from the Mediator scandal.
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest appointments
-
New president for Spanish Society of Pharmacology
His research focuses on the study of inflammatory processes, mediators, leukocyte-endothelium interactions and leukocyte infiltration in various pathologies.
-
Peix appoints online marketing manager
Kruger “sees herself as a mediator between traditional and digital communications”, said Peix in a statement.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
SEVEN STONES COLLECTIVE
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
